News | August 19, 2025
Pfizer’s sickle cell disease candidate fails Phase III trial
Inclacumab was generally well tolerated in THRIVE-131
Inclacumab was generally well tolerated in THRIVE-131
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
Attorney General Ken Paxton sued pharmaceutical giant Eli Lilly for bribing and illegally inducing medical providers to prescribe its most profitable drugs
Glenmark USA is named in multiple antitrust and consumer protection lawsuits, including class actions, consolidated in the Eastern District of Pennsylvania, U.S
Reinforcing commitment to ethical and sustainable growth
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Currently focused on platform-related queries, elva.AI is the first step in ekincare’s broader roadmap
The Q-Switched Nd:YAG system is suitable for all skin types and offers versatility in treating dermal and epidermal pigmentation
Subscribe To Our Newsletter & Stay Updated
